Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma
Trial Parameters
Brief Summary
This is a multi-site study of the pharmacodynamic effects and efficacy of metformin in children and young adults with recurrent or progressive Posterior Fossa Group A (PFA) ependymoma.
Eligibility Criteria
Inclusion Criteria: 1. Participants must have recurrent or progressive posterior fossa A (PFA) ependymoma following surgery AND radiation treatment (RT). 2. Participants must have a diagnosis of PFA ependymoma either at initial diagnosis or at recurrence. Any number of previous recurrences are permissible provided the participant meets other enrollment criteria. 3. Participants must have adequate tumor tissue available from initial diagnosis or from pre- trial enrollment. Formalin-fixed paraffin-embedded (FFPE) material (1 full block) should be provided. If FFPE material is not available, 10 unstained slides with an accompanying hematoxylin and eosin (H\&E) report should be provided. Target Validation (TV) Phase: o Participants are candidates to undergo elective surgery for removal of all or a portion of their recurrent/progressive tumor. Efficacy Phase: * Participant must have measurable disease; this will be defined as lesions that can be accurately measured in two dimensions (longes